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Perspective
D
espite the remarkable 
achievements in discovery and 
development of antiretroviral 
agents for the treatment of infection 
with human immunodeﬁciency virus 
type 1 (HIV-1), drug resistance remains 
a major reason for viral rebound and 
treatment failure. Therefore, resistance 
testing has become an important 
tool in clinical decision making. HIV 
genotype testing, to look for mutations 
that confer drug resistance, is now 
widely established as the standard 
of care to guide treatment in the 
context of both primary infection and 
virological failure [1]. 
Phenotypic resistance testing involves 
drug susceptibility measurements in 
cell-based in vitro assays. Differences 
between wild type viral strains with 
no known resistance-conferring 
mutations and patient-derived HIV 
variants are usually expressed in drug 
concentrations required to inhibit 
virus replication by 50% (IC50). Both 
genotypic and phenotypic assays 
provide important information that 
helps to predict changes in drug 
efﬁcacies in the context of resistance. 
HIV genotyping is more widespread, in 
part because of its lower cost. 
Limitations of Genotypic Testing
Several clinical trials showed a 
beneﬁcial effect of resistance testing 
[2–6]. However, there are also intrinsic 
limitations and caveats associated with 
the practical use of genotyping. 
First of all, the genotyping data 
need to be translated into predicted 
levels of resistance to antiretrovirals, 
which requires interpretation. Analysis 
of genotypic testing is complicated 
when treatment has lead to complex 
resistance patterns with multiple 
mutations [7]. The effect of a single 
amino acid substitution on measurable 
changes in drug susceptibility can 
sometimes markedly vary depending 
on the presence of other mutations 
or polymorphisms. Resistance or 
decreased susceptibility to a given drug 
is therefore a continuum between the 
two extremes of “fully sensitive” and 
“no antiretroviral activity,” rather than 
an all-or-nothing phenomenon. 
Drug hypersusceptibility (see 
Glossary) and resensitization effects 
add to the problems in translating 
genotypes into phenotypes. For 
instance, the M184V mutation in 
HIV-1 reverse transcriptase (RT) 
confers a high level of resistance to 
lamivudine (3TC) and was also shown 
to counteract resistance to zidovudine 
(AZT) in the presence of thymidine 
analogue–associated mutations 
(TAMs) [8]. Antagonistic mutations 
and complex resistance patterns 
are important reasons for apparent 
genotype–phenotype discordances 
that are often described when both 
genotypic and phenotypic test results 
are available. 
Moreover, routine sequencing 
protocols do not cover the entire 
HIV genome and therefore standard 
genotyping systems need to be seen as 
surrogates of the whole genome. For 
practical, technical, and economical 
reasons, most assays involve only 
portions of the drug target. 
Two classes of commonly used 
antiretroviral drugs target RT, the 
enzyme that copies HIV’s RNA genome 
into DNA, leading to viral persistence 
in the host cell and ultimately to 
production of new HIV particles. 
Nucleoside analogue RT inhibitors 
(NRTIs), the ﬁrst of these drug classes, 
are incorporated into the DNA that is 
being synthesized and act by preventing 
its further growth. The incorporated 
NRTI acts like a chain-terminator that 
prevents further addition of natural 
nucleotides. The second class of 
drugs, non-nucleoside RT inhibitors 
(NNRTIs), bind to RT in a manner 
that alters the active site and prevents 
it from performing DNA synthesis. The 
N-terminal portion of the RT enzyme 
constitutes the polymerase active site 
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Linked Research Article 
This Perspective discusses the 
following new study published in PLoS
Medicine:
Yap SH, Sheen CW, Fahey J, Zanin 
M, Tyssen D, et al. (2007) N348I in the 
connection domain of HIV-1 reverse 
transcriptase confers zidovudine and 
nevirapine resistance. PLoS Med 4(12): 
e335. doi:10.1371/journal.pmed.0040335
Analyzing HIV sequences from a 
Canadian cohort, Gilda Tachedjian and 
colleagues identify a common mutation 
in a little-studied domain of reverse 
transcriptase that confers resistance to 
two drug classes.PLoS Medicine  |  www.plosmedicine.org 1859 December 2007  |  Volume 4  |  Issue 12  |  e346
and includes the binding site for both 
NRTIs and NNRTIs. Because most 
NRTI and NNRTI resistance mutations 
are clustered around the polymerase 
active site and the proximate binding 
site for NNRTIs [9–12], routine 
genotypic analysis of mutations in this 
protein includes only about 300 or 
even fewer of the N-terminal amino 
acids, even though the entire HIV-1 RT 
protein encompasses 560 amino acids. 
However, growing evidence suggests 
that mutations outside the N-terminal 
region can likewise contribute to 
resistance to RT inhibitors. 
Mutations in Connection and 
Ribonuclease H Domains of 
HIV-1 RT
The C-terminal region of RT includes 
the “connection” domain (289–423) 
and the ribonuclease H (RNase H) 
domain (424–560). RNase H activity is 
required to cleave the RNA moiety of 
RNA/DNA replication intermediates. 
G333D/E polymorphisms have been 
associated with dual resistance to AZT 
and 3TC [13,14], and Y318F has been 
linked to decreased susceptibility to 
NNRTIs [15]. More recently, Nikolenko 
and colleagues have shown that 
mutations in the C-terminal domains 
of HIV-1 RT can markedly increase the 
level of resistance to AZT, provided 
that these amino acid substitutions are 
combined with classic TAMs [16]. 
Nikolenko and colleagues postulated 
an intriguing mechanism that may 
help to explain the increase in AZT 
resistance [17]. Previous studies 
have shown that chain-termination 
with AZT, and to a lesser extent also 
with other NRTIs, can be reversed. 
HIV-1 RT is capable of removing the 
incorporated AZT in the presence of 
physiologically relevant concentrations 
of pyrophosphate or adenosine 
triphosphate (ATP) that can act 
as a pyrophosphate donor. TAMs 
containing mutant RT enzymes were 
shown to increase rates of the ATP-
dependent excision reaction when 
compared with wild-type HIV-1 RT, 
which translates into resistance to AZT 
[18]. Nikolenko and colleagues then 
argued that AZT chain-termination 
might be permanent when the RT-
associated RNase H activity has 
completely degraded the template 
strand. The complex of RT, the chain-
terminated primer, and the cleaved 
template will simply dissociate under 
these conditions. Thus, AZT resistance 
could be enhanced by diminishing 
RNase H cleavage, which, in turn, 
would provide more time for the 
excision reaction. 
Indeed, several of the newly 
identiﬁed mutations were shown to 
decrease template switching [19], 
which is indicative of reductions in 
RNase H cleavage. Most importantly, 
mutations E312Q, G335C/D, N348I, 
A360I/V, V365I, and A376S in the 
connection domain of HIV-1 RT were 
associated with increased resistance 
to AZT, and these mutations were 
identiﬁed in clinical samples of HIV-
infected individuals [16]. In contrast, 
RNase H mutations that are seen in the 
clinic do not appear to contribute to 
AZT resistance [16,20].
Independent evidence for the role 
of mutations in the connection and 
RNase H domains in AZT resistance 
has been derived from in vitro 
selection experiments [21]. The 
authors reported the appearance of 
A371V in the connection domain and 
Q509L in the RNase H domain under 
the selective pressure of AZT. Both 
mutations, in conjunction with TAMs, 
increased resistance to AZT and also 
caused increased cross-resistance to 
3TC and abacavir. In spite of these 
advances in the characterization of the 
C-terminal region of HIV-1 RT and 
its involvement in NRTI resistance, 
the clinical relevance of connection 
and RNase H mutations has remained 
elusive [22,23].
A New Study of the Connection 
Mutation N348I
In this issue of PLoS Medicine, Soo-Huey 
Yap et al. report on a detailed clinical 
and biochemical characterization 
of the connection mutation N348I 
[24], which turned out to be a highly 
interesting mutation in many ways. 
Clinical samples were collected at the 
British Columbia Centre for Excellence 
in HIV/AIDS, in Vancouver, Canada. 
The authors compared sequences 
from individuals with known treatment 
history (n = 1,009) with patient samples 
from treatment-naïve individuals 
(n = 368) and found that N348I is 
highly prevalent among treatment-
experienced patients. With a 12% 
prevalence, it ranked as the 9th most 
prevalent RT-associated mutation in 
this group of individuals. 
N348I was highly associated with 
M184V and several different TAMs; 
however, analysis of 31 patient samples 
with no mutations present at baseline 
and known treatment history suggests 
that this mutation emerges early after 
initiation of antiretroviral therapy. 
Treatment with AZT and combined 
treatment with AZT and the NNRTI 
nevirapine (NVP) was associated with 
an increased detection of N348I. 
Brehm et al., 2007 [21] Selection of 
mutations in the connection and RNase 
H domains of human immunodeﬁciency 
virus type 1 reverse transcriptase that 
increase resistance to 3’-azido-3’-
dideoxythymidine. J Virol 81: 7852-7859.
First report on the in vitro selection of 
AZT resistance–conferring mutations in 
the connection and RNase H domains. 
Nikolenko et al., 2007 [16] Mutations 
in the connection domain of HIV-1 
reverse transcriptase increase 3’-azido-
3’-deoxythymidine resistance. Proc Natl 
Acad Sci U S A 104: 317-322.
Shows for the ﬁrst time that the C-
terminal domains of HIV-1 RT can 
contribute to AZT resistance in the 
context of clinical isolates. 
Nikolenko et al., 2005 [17] Mechanism 
for nucleoside analog-mediated 
abrogation of HIV-1 replication: balance 
between RNase H activity and nucleotide 
excision. Proc Natl Acad Sci U S A 102: 
2093-2098.
Provides the ﬁrst evidence to suggest 
that diminished RNase H cleavage may 
increase resistance to AZT.
Zolopa et al., 2005 [7] Accuracy, 
precision, and consistency of expert 
HIV type 1 genotype interpretation: an 
international comparison (The GUESS 
Study). Clin Infect Dis 41: 92-99.
Comprehensive study on accuracy of 
expert HIV genotype interpretation 
in the context of complex mutational 
patterns.
Meyer et al., 1999 [18] A mechanism of 
AZT resistance: an increase in nucleotide-
dependent primer unblocking by mutant 
HIV-1 reverse transcriptase. Mol Cell 4: 
35-43.
First study describing the ATP-dependent 
excision reaction as a mechanism for AZT 
resistance.
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The authors further report that the 
appearance of N348I was associated 
with a signiﬁcant increase in viral load, 
which was comparable with each of the 
individual classic TAMs at positions 
219, 215, 210, 70, 67, and 41.
In vitro susceptibility studies 
with HIV-1 constructs that were 
generated by site-directed mutagenesis 
corroborate their ﬁndings. The 
authors report a moderate, 2-fold 
increase in AZT resistance when 
wild-type virus is compared with 
the N348I mutant variant, and an 
increase in AZT resistance is seen 
when N348I is introduced against a 
background of TAMs. However, the 
data make clear that N348I does not 
counteract the resensitization effects 
of M184V, which is also consistent 
with previous ﬁndings [16,20]. N348I 
also conferred resistance to NVP (8-
fold), and this effect was ampliﬁed 
against a background of K103N. With 
the exception of rare, ﬁtness-deﬁcient 
mutations, and perhaps the effects of 
changes at position 181 on stavudine, 
this is the ﬁrst example of dual 
resistance to NRTIs and NNRTIs. 
Possible Underlying Mechanisms
Yap et al. have also addressed the 
potential biochemical mechanism for 
how N348I confers drug resistance—
they provide evidence to show that 
this mutation can augment levels 
of excision of AZT. Increased rates 
of excision are selectively seen on 
RNA/DNA substrates when TAM-
containing mutant RT was compared 
with TAMs/N348I. Such differences are 
not evident on DNA/DNA substrates, 
which pointed to an involvement of the 
RT-associated RNase H activity in AZT 
resistance. Indeed, mutant enzymes 
containing N348I show signiﬁcant 
reductions in RNase H cleavage. Thus, 
the biochemical data are consistent 
with the notion that diminished RNase 
H cleavage facilitates excision by 
delaying degradation of the template.
Implications and Outlook
The multidisciplinary approach is a 
major strength of Yap and colleagues’ 
study. Their retrospective clinical 
studies are in good agreement with in 
vitro susceptibility measurements and 
biochemical mechanistic analyses. The 
combined data provide strong evidence 
to show that N348I can contribute 
to AZT resistance. N348I may not be 
considered as a “secondary mutation” 
that solely improves the replication 
capacity of resistant viruses, because 
this mutation appears to emerge early 
after initiation of therapy and the 
diminished RNase H activity combined 
with elevated levels of excision provide 
a plausible molecular mechanism. At 
the same time, the decrease in AZT 
susceptibility is relatively small in the 
absence of TAMs. In this context, 
the authors argue that the individual 
effect of each of the known TAMs is 
likewise subtle. It is therefore tempting 
to categorize N348I as yet another 
TAM. However, there are noticeable 
differences between classic TAMs and 
N348I. The classic TAMs at positions 
219, 215, 210, 41, 67, and 70 are 
clustered around the putative binding 
site of the pyrophosphate donor ATP 
that promotes excision of AZT. In 
contrast, N348I is distant from the 
active site and the NNRTI binding 
site. As the authors point out, the 
structural mechanism by which N348I 
confers resistance to AZT remains to be 
delineated. Moreover, the mechanism 
and structural basis for NNRTI 
resistance in association with N348I 
have yet to be addressed as well.
In spite of these open questions, 
the data presented in this study help 
to shed light on complex resistance 
patterns and provide a rationale 
for including the N348I mutation 
in genotypic testing. Hachiya and 
colleagues have recently identiﬁed 
the N348I mutation in clinical isolates 
that showed decreased susceptibility to 
NVP in the absence of known NNRTI-
associated mutations [25]. Thus, the 
inclusion of N348I, and possibly also 
other connection mutations, may be 
considered in the context of routine 
genotyping. Clinical studies that are 
designed to assess a potential beneﬁt 
of including connection mutations in 
HIV resistance testing are required 
to further address this issue. It will 
likewise be important to gather similar 
information on the role of other 
connection mutations and possibly 
RNase H–associated mutations. The 
various locations of known C-terminal 
mutations in the RT enzyme suggest 
the involvement of different underlying 
mechanisms.  
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